No Bellwether For Diabetics In Insulin Case Despite Virus Risk
Diabetics prepping their sprawling case over insulin prices for a 2022 trial have lost their bid to funnel their claims through a bellwether strategy, although counsel for the patients said they're...To view the full article, register now.
Already a subscriber? Click here to view full article